Developing new drugs is not for the faint-hearted. “It’s a pretty perilous journey,” says Paul Nioi, vice-president of discovery and translational research at Alnylam Pharmaceuticals. “It’s expensive ...

Globally, pressure is increasing for healthcare systems to deliver on the promise of genomic medicine to improve patient well-being. Although primary care is the ideal setting for leading this effort, ...